A Phase 2 interventional study of Selinexor in Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL), sponsored by Karyopharm Therapeutics Inc. Terminated at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.
Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Lymphoma, T-Cell, Peripheral with a site in Australia — 3 open to participants now, 4 under way, 1 of them phase 3. Lymphoma, T-Cell, Peripheral · Australia.
Among the 16 studies in Lymphoma, T-Cell, Peripheral with a site in Australia, this one is the 13th largest by enrollment, is one of 2 that started in 2015, is one of 6 in phase 2, and was the 6th registered.
372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.
Browse Lymphoma, T-Cell, Peripheral studies →3 of the 16 studies in Lymphoma, T-Cell, Peripheral with a site in Australia are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in Australia, United States, Belgium and 2 more countries
Ages 18+
Corvus Pharmaceuticals, Inc. · Sites in Australia, United States, Canada
Ages 18+
AstraZeneca · Sites in Australia, United States, Brazil and 8 more countries
Ages 12+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 9 · Phase 3 3
First in 2001; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 44 across 328 interventional studies indexed under Lymphoma, T-Cell, Peripheral.
Median enrollment 120 across the 16 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 16 have an industry lead sponsor. The 10 most frequent:
Karyopharm Therapeutics Inc is the lead sponsor of 37 studies on the registry; 4 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.
Karyopharm Therapeutics Inc has 3 studies filed under Lymphoma, T-Cell, Peripheral — fewer than ten, so there is no comparison to draw.
1 of the studies in Lymphoma, T-Cell, Peripheral with a site in Australia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06561048Phase 3Corvus Pharmaceuticals, Inc.Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Lymphoma, T-Cell, Peripheral with a site in Australia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a single-arm, multi-center, open-label phase 2 study of the SINE™ compound selinexor given orally to patients with relapsed or refractory PTCL or CTCL.
Approximately 60 patients with relapsed or refractory PTCL or CTCL who meet the eligibility criteria and have none of the exclusion criteria will be enrolled to receive selinexor until either disease progression or intolerance has occurred.
This is a single-arm, multi-center, open-label phase 2 study of the SINE™ compound selinexor given orally to patients with relapsed or refractory PTCL or CTCL.
Approximately 60 patients with relapsed or refractory PTCL or CTCL who meet the eligibility criteria and have none of the exclusion criteria will be enrolled to receive selinexor until either disease progression or intolerance has occurred.
Enrolled patients will be given selinexor as an oral fixed 60 mg dose (equivalent to \~35 mg/m²) on Days 1 and 3 of Weeks 1-4 of each 4-week cycle (total 8 doses per cycle).
There is no maximum treatment duration. Patients will receive supportive therapy to mitigate selinexor side effects, as well as best supportive care (BSC).
Patients enrolled under Protocol Versions \<3.0 were to receive selinexor orally, at a fixed dose of 60 mg (equivalent to \~35 mg/m²) on Days 1 and 3 of Weeks 1-3 of each 4-week cycle (total of 6 doses per cycle). Selinexor was not taken during Week 4.
For all patients enrolled in this study (regardless of the protocol version) who continued onto Cycle 3 and forward, the dose was to be increased by 20 mg to 80 mg (administered on Days 1 and 3 of Weeks 1-4), only after consultation with the Sponsor's Medical Monitor.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
60 mg dose (equivalent to \~35 mg/m²)
Drug: Selinexor
20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle (Protocol V.3.0). 20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-3 of each 4-week cycle (Protocol V.\<3.0). Number of Cycles: up to 12 but there is no maximal duration for treatment.
Also known as: KPT-330
Overall Response Rate (ORR)
Overall Response (OR) = Complete Response (CR) + Partial Response (PR). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment. Progression was defined as the first occurrence of progressive disease (PD) per the revised response criteria. Clinical disease progression in the absence of formal criteria for PD must be documented by a physician.
Time frame: Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.
Best Overall Response: Complete Response (CR)
Patients who achieved CR (disappearance of all detectable evidence of disease). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.
Time frame: Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.
Best Overall Response: Partial Response (PR)
Patients whose best overall response to study treatment was PR (regression of measurable disease and no new sites). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.
Time frame: Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.
Best Overall Response: Stable Disease (SD)
Patients whose best overall response to study treatment was SD (failure to attain criteria needed for CR or PR, or to meet criteria for PD). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.
Time frame: Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.
Best Overall Response: Progressive Disease (PD)
Patients whose best overall response to study treatment was PD. Progression was defined as the first occurrence of progressive disease (PD). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment. Clinical disease progression in the absence of formal criteria for PD must be documented by a physician.
Time frame: Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.
Best Overall Response: Not Evaluable (NE)
Patients who could not be assessed quantitatively for disease response for any reason.
Time frame: Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.
Duration of Stable Disease, Including Patients With Partial Response
Duration of time from the date of start of study treatment to the date of disease progression. Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.
Time frame: Date of start of study treatment to date of progression. Patients without documented PD are censored on date of last radiologic assessment.
Disease Control Rate (DCR)
Percentage of patients who have CR, PR, or SD lasting ≥ 8 weeks. Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.
Time frame: Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.
Progression Free Survival (PFS)
Duration of time from start of study treatment to date of disease progression or death from any cause.
Time frame: Study treatment start date to date of disease progression or date of death. Patients without documented PD are censored on date of last radiologic assessment.
| Milestone | Selinexor (PTCL) | Selinexor (CTCL) | Selinexor (CTCL) 8 Doses/Cycle |
|---|---|---|---|
| Started | 9 | 6 | 1 |
| Completed | 0 | 0 | 0 |
| Not completed | 9 | 6 | 1 |
| Withdrew: Adverse event | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 3 | 1 |
| Withdrew: Progression of disease | 6 | 2 | 0 |
Overall Response (OR) = Complete Response (CR) + Partial Response (PR). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment. Progression was defined as the first occurrence of progressive disease (PD) per the revised response criteria. Clinical disease progression in the absence of formal criteria for PD must be documented by a physician.
| Percentage of participants | Selinexor (PTCL) | Selinexor (CTCL) |
|---|---|---|
| Overall Response Rate (ORR) | 11.1 (1.2 to 36.8) | 14.3 (1.5 to 45.3) |
Patients who achieved CR (disappearance of all detectable evidence of disease). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.
| Participants | Selinexor (PTCL) | Selinexor (CTCL) |
|---|---|---|
| Best Overall Response: Complete Response (CR) | 0 | 0 |
Patients whose best overall response to study treatment was PR (regression of measurable disease and no new sites). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.
| Participants | Selinexor (PTCL) | Selinexor (CTCL) |
|---|---|---|
| Best Overall Response: Partial Response (PR) | 1 | 1 |
Patients whose best overall response to study treatment was SD (failure to attain criteria needed for CR or PR, or to meet criteria for PD). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.
| Participants | Selinexor (PTCL) | Selinexor (CTCL) |
|---|---|---|
| Best Overall Response: Stable Disease (SD) | 2 | 4 |
Patients whose best overall response to study treatment was PD. Progression was defined as the first occurrence of progressive disease (PD). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment. Clinical disease progression in the absence of formal criteria for PD must be documented by a physician.
| Participants | Selinexor (PTCL) | Selinexor (CTCL) |
|---|---|---|
| Best Overall Response: Progressive Disease (PD) | 2 | 0 |
Patients who could not be assessed quantitatively for disease response for any reason.
| Participants | Selinexor (PTCL) | Selinexor (CTCL) |
|---|---|---|
| Best Overall Response: Not Evaluable (NE) | 4 | 2 |
Duration of time from the date of start of study treatment to the date of disease progression. Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.
| Days | Selinexor (PTCL) | Selinexor (CTCL) |
|---|---|---|
| Duration of Stable Disease, Including Patients With Partial Response | 120.5 (111.0 to 130.0) | 112.0 (85.0 to 225.0) |
Percentage of patients who have CR, PR, or SD lasting ≥ 8 weeks. Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.
| Percentage of participants | Selinexor (PTCL) | Selinexor (CTCL) |
|---|---|---|
| Disease Control Rate (DCR) | 33.3 (12.9 to 59.9) | 71.4 (40.4 to 92.1) |
Duration of time from start of study treatment to date of disease progression or death from any cause.
| Days | Selinexor (PTCL) | Selinexor (CTCL) |
|---|---|---|
| Progression Free Survival (PFS) | 111.0 (41.0 to 130.0) | 112.0 (85.0 to 225.0) |
Collected over Day of onset after the first dose of study treatment through 30 days following the last dose of study treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Selinexor (PTCL) | 3/9 (33.3%) | 8/9 (88.9%) | 9/9 (100%) |
| Selinexor (CTCL) | 1/7 (14.3%) | 1/7 (14.3%) | 7/7 (100%) |
| Event | Selinexor (PTCL) | Selinexor (CTCL) |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 2/9 | 0/7 |
| FallInjury, poisoning and procedural complications | 0/9 | 1/7 |
| AnemiaBlood and lymphatic system disorders | 1/9 | 0/7 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 1/9 | 0/7 |
| PneumoniaInfections and infestations | 1/9 | 0/7 |
| Wound Infection StaphylococcalInfections and infestations | 1/9 | 0/7 |
| AphasiaNervous system disorders | 1/9 | 0/7 |
| LethargyNervous system disorders | 1/9 | 0/7 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/9 | 0/7 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 1/9 | 0/7 |
| Event | Selinexor (PTCL) | Selinexor (CTCL) |
|---|---|---|
| NauseaGastrointestinal disorders | 5/9 | 5/7 |
| Decreased AppetiteMetabolism and nutrition disorders | 2/9 | 5/7 |
| FatigueGeneral disorders | 4/9 | 5/7 |
| ConstipationGastrointestinal disorders | 1/9 | 4/7 |
| DiarrheaGastrointestinal disorders | 2/9 | 1/7 |
| VomitingGastrointestinal disorders | 2/9 | 1/7 |
| AnaemiaBlood and lymphatic system disorders | 2/9 | 0/7 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/9 | 0/7 |
| NeutropeniaBlood and lymphatic system disorders | 2/9 | 0/7 |
| PruritusSkin and subcutaneous tissue disorders | 2/9 | 1/7 |
| Age, Continuous(years) | Selinexor (PTCL) | Selinexor (CTCL) | Total |
|---|---|---|---|
| Median | 65 (51 to 83) | 74 (59 to 84) | 69 (51 to 84) |
| Sex: Female, Male(Participants) | Selinexor (PTCL) | Selinexor (CTCL) | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 7 | 5 | 12 |
| Ethnicity (NIH/OMB)(Participants) | Selinexor (PTCL) | Selinexor (CTCL) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 8 | 7 | 15 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Race (NIH/OMB)(Participants) | Selinexor (PTCL) | Selinexor (CTCL) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 8 | 6 | 14 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
Plan to share: Yes
No publications or documents are linked to this record.
The record gives a start of Feb 2015, a primary completion of Jan 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2018, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selinexor
Lymphoma, T-Cell, Peripheral →